Molecular characterization of the dopamine transporter
- PMID: 8480373
- DOI: 10.1016/0165-6147(93)90029-j
Molecular characterization of the dopamine transporter
Abstract
Neurotransmission, which represents chemical signalling between neurons, usually takes place at highly differentiated anatomical structures called synapses. To fulfill both the time and space confinements required for optimal neurotransmission, highly specialized proteins, known as transporters or uptake sites, occur and operate at the presynaptic plasma membrane. Using the energy provided by the Na+ gradient generated by the Na+/K(+)-transporting ATPase, these transporters reuptake the neurotransmitters soon after their release, thereby regulating their effective concentrations at the synaptic cleft and the availability of neurotransmitters for a time-dependent activation of both pre- and postsynaptic receptors. The key role these proteins play in normal neurotransmission is further emphasized when the physiological and social consequences of drugs that interfere with the function of these transporters, such as the psychostimulants (e.g. amphetamine and cocaine) or the widely prescribed antidepressant drugs, are considered. In this review, Bruno Giros and Marc Caron elaborate on the potential consequences of the recent molecular cloning of the dopamine and related transporters and summarize some of the interesting properties that are emerging from this growing family of Na(+)- and Cl(-)-dependent transporters.
Similar articles
-
Pharmacology and regulation of the neuronal dopamine transporter.Eur J Pharmacol. 1997 Apr 11;324(1):1-10. doi: 10.1016/s0014-2999(97)00065-4. Eur J Pharmacol. 1997. PMID: 9137907 Review.
-
Cloning and expression of a cocaine-sensitive rat dopamine transporter.Science. 1991 Oct 25;254(5031):578-9. doi: 10.1126/science.1948035. Science. 1991. PMID: 1948035
-
The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines.Mol Pharmacol. 2001 Jan;59(1):83-95. doi: 10.1124/mol.59.1.83. Mol Pharmacol. 2001. PMID: 11125028
-
Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems.Pharmacol Ther. 2001 Oct;92(1):21-55. doi: 10.1016/s0163-7258(01)00158-9. Pharmacol Ther. 2001. PMID: 11750035 Review.
-
Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance.Clin Neuropharmacol. 1994 Feb;17(1):1-22. doi: 10.1097/00002826-199402000-00001. Clin Neuropharmacol. 1994. PMID: 8149355 Review.
Cited by
-
Oligomerization of Monoamine Transporters.Subcell Biochem. 2024;104:119-137. doi: 10.1007/978-3-031-58843-3_7. Subcell Biochem. 2024. PMID: 38963486 Review.
-
Predicting therapeutic and side effects from drug binding affinities to human proteome structures.iScience. 2024 May 20;27(6):110032. doi: 10.1016/j.isci.2024.110032. eCollection 2024 Jun 21. iScience. 2024. PMID: 38868195 Free PMC article.
-
Amphetamine Induces Sex-Dependent Loss of the Striatal Dopamine Transporter in Sensitized Mice.eNeuro. 2024 Jan 29;11(1):ENEURO.0491-23.2023. doi: 10.1523/ENEURO.0491-23.2023. Print 2024 Jan. eNeuro. 2024. PMID: 38164591 Free PMC article.
-
Diagnostic accuracy of 18F-FP-CIT PET for clinically uncertain Parkinsonian syndrome.Sci Rep. 2023 Sep 12;13(1):15069. doi: 10.1038/s41598-023-42135-9. Sci Rep. 2023. PMID: 37700061 Free PMC article.
-
Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson's disease patients and healthy controls.BMC Med. 2023 Jul 25;21(1):272. doi: 10.1186/s12916-023-02994-5. BMC Med. 2023. PMID: 37491235 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
